NEW YORK (GenomeWeb) – Vermillion said today that it has received a CE mark for its Overa ovarian cancer test, a second-generation version of its OVA1 test.
The company is now cleared to market Overa in the EU, and is "actively identifying global partnerships" to sell the test, Vermillion President and CEO Valerie Palmieri said in a statement.
Like OVA1, Overa is intended for triaging patients with ovarian adnexal masses as part of preoperative evaluations to determine the likelihood that a mass is cancerous.
According to Vermillion, Overa offers several improvements over the existing OVA1 test, including a 28 percent improvement in specificity, a 29 percent improvement in positive predictive value, and a 20 percent improvement in overall clinical accuracy.